Background and purpose The COVID‐19 pandemic, caused by severe acute respiratory
syndrome coronavirus type 2 (SARS‐CoV‐2), rapidly spread across the globe. Tremendous …

Abstract SARS-CoV-2, the virus responsible for COVID-19, has caused numerous deaths
worldwide and poses significant challenges. Researchers have recently studied a new …

Background Large clinical trials on drugs for hospitalized coronavirus disease 2019 (COVID-
19) patients have shown significant effects on mortality. There may be a discrepancy with the …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of
coronavirus disease 2019 (COVID-19), has radically altered daily life. Effective antiviral …

Potentially significant drug candidates often face elimination from consideration due to the
lack of an effective method for systemic delivery. The poor solubility of these candidates has …

Numerous treatments exist for COVID-19, the illness caused by SARS-CoV-2 virus, although
most are not well established; among these are several small molecule antiviral agents …

Background: To date, no oral antiviral drug has proven to be beneficial in hospitalized
patients with COVID-19. Methods: In this randomized, controlled, open-label, platform trial …

Aprotinin (APR) was discovered in 1930. APR is an effective pan-protease inhibitor, a typical
“magic shotgun”. Until 2007, APR was widely used as an antithrombotic and anti …

Introduction The randomized, placebo-controlled, double-blind MOVe-OUT trial
demonstrated molnupiravir (800 mg every 12 h for 5 days) as safe and effective for …

In a short time, several types of injectable and oral therapeutics have been developed and
used to effectively manage patients with coronavirus disease 2019 (COVID-19). BEN815 is …